Dr. Rice is a leader in the development of targeted delivery systems for gene transfer to the liver. His R01-funded research uses a high-affinity triantennary N-glycan attached to the PEG-peptide to trigger hepatocytic endocytosis of nanoparticles via the asialoglycoprotein receptor. His group also focuses on developing nanoparticles that target somatostatin receptor-expressing cells in the periphery. As this receptor is expressed on exocrine acinar cells of the pancreas, it represents unique opportunities for gene therapy of CFRD in the CF ferret and pig models.